IMCC vs. CRVO, ATRA, INMB, KRON, AVTX, ZIVO, RENB, VTVT, QNTM, and APLT
Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include CervoMed (CRVO), Atara Biotherapeutics (ATRA), INmune Bio (INMB), Kronos Bio (KRON), Avalo Therapeutics (AVTX), ZIVO Bioscience (ZIVO), Renovaro (RENB), vTv Therapeutics (VTVT), Quantum Biopharma (QNTM), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry.
IM Cannabis vs. Its Competitors
CervoMed (NASDAQ:CRVO) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
IM Cannabis has higher revenue and earnings than CervoMed. IM Cannabis is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.
CervoMed presently has a consensus price target of $22.57, indicating a potential upside of 204.61%. Given CervoMed's stronger consensus rating and higher probable upside, equities analysts plainly believe CervoMed is more favorable than IM Cannabis.
In the previous week, CervoMed had 1 more articles in the media than IM Cannabis. MarketBeat recorded 1 mentions for CervoMed and 0 mentions for IM Cannabis. CervoMed's average media sentiment score of 1.08 beat IM Cannabis' score of 0.94 indicating that CervoMed is being referred to more favorably in the media.
IM Cannabis has a net margin of -9.10% compared to CervoMed's net margin of -200.57%. CervoMed's return on equity of -44.07% beat IM Cannabis' return on equity.
25.2% of CervoMed shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 35.4% of CervoMed shares are owned by company insiders. Comparatively, 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
CervoMed has a beta of -0.75, suggesting that its stock price is 175% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.
Summary
CervoMed beats IM Cannabis on 10 of the 16 factors compared between the two stocks.
Get IM Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IM Cannabis Competitors List
Related Companies and Tools
This page (NASDAQ:IMCC) was last updated on 7/18/2025 by MarketBeat.com Staff
Free IMCC Stock Alerts